Efficacy and Safety Outcomes of Extended Criteria Donor Kidneys by Subtype: Subgroup Analysis of BENEFIT‐EXT at 7 Years After Transplant

The phase III Belatacept Evaluation of Nephroprotection and Efficacy as First‐Line Immunosuppression Trial–Extended Criteria Donors Trial (BENEFIT‐EXT) study compared more or less intensive belatacept‐based immunosuppression with cyclosporine (CsA)–based immunosuppression in recipients of extended c...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Am J Transplant
Autors principals: Florman, S., Becker, T., Bresnahan, B., Chevaile‐Ramos, A., Carvalho, D., Grannas, G., Muehlbacher, F., O'Connell, P. J., Meier‐Kriesche, H. U., Larsen, C. P.
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2016
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5215636/
https://ncbi.nlm.nih.gov/pubmed/27232116
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/ajt.13886
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars